Table 2:
Ongoing Vitamin D clinical trials
| Trial name | Population | Intervention | Main outcomes | Results expected | Country |
|---|---|---|---|---|---|
| VIDAL (Vitamin D and Longevity trial) | 20,000 adults, 65–85 years old | 100,000 IU D3 monthly, placebo or open control | Mortality, morbidity (infections, doctor’s visits, cancer) and vitamin D levels | 2020 | United Kingdom |
| SIMPLIFIED (Survival Improvement with Cholecalciferol in Patients on Dialysis) | 4,200 adults, aged > 18 years | Cholecalciferol 60,000 IU fortnightly | Mortality, health-related quality of life, hospital admission, cardiovascular events, cancer incidence | 2023 | United Kingdom |
| TARGET-D (Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients) | 890 adults, aged > 18 years | Target 25D levels > 40ng/mL with cholecalciferol or standard of care (no intervention) | Mortality, myocardial infarction, heart failure hospitalization and cerebral vascular accident | 2021 | United States |
| FIND (Finnish Vitamin D Trial) | 2495 adults, men > 60 years and women > 65 years | 3200 D3 daily, 1600 D3 daily or placebo | Cardiovascular disease, cancer and diabetes mellitus | 2019 | Finland |
| Effect of Vitamin D Supplementation in Patients with Heart Failure and Vitamin D Deficiency | 60 adults, aged 45 to 85 years | 5 000IU vitamin D D vs placebo | Myocardial structure and function by MRI, myocardial infarction | 2019 | Mexico |
| Effect of Vitamin D on Ventricular Remodeling in Patients with Acute Myocardial Infarction (VITDAMI) | 144 adults, aged 40 to 85 years | 15,690 IU Calcifediol vs placebo | Change in cardiac remodeling by MRI, echo parameters | 2019 | Spain |
| Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes | 123 adults, aged 30 to 70 years | 1000U vitamin D and 360 magnesium vs 1000U vitamin D vs placebo | PTH levels, inflammatory cytokines, lipid profile, blood pressure, serum osteocalcin | 2020 | United States |
| Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy | 412 adults, aged > 18 years | 3000 IU vitamin D daily or 4000 IU daily with and without prenatal vitamins | Blood pressure, new onset proteinuria, thrombocytopenia, impaired liver function testing, renal insufficiency | 2019 | United States |
| DO-HEALTH (Vitamin D3-Omega3-Home Exercise – Healthy Ageing and Longevity Trial) | 2157 adults, aged 70 years and older | 1) 2000 IU vitamin D compared to placebo; 2) 1g omega-3 fatty acid compared to placebo; 3) home exercise of 30 minutes 3 times a week compared to control exercise program 30 minutes 3 times a week | Incident non-vertebral fractures, functional decline (measured by short physical performance test battery), blood pressure, cognitive decline (by montreal cognitive assessment), immunity (by rate of any infections) | 2019 | Switzerland |